ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
US Tech 100
20,836.00
1.31%
Dow Jones
42,840.26
1.18%
Brent Oil
72.72
0.00%
Bitcoin
96,135.47
-1.10%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ocular Therapeutix Inc (OCUL) Quote

Ocular Therapeutix Inc

Ocular Therapeutix Inc (OCUL)

NASDAQ
8.50
0.05
(0.59%)
Closed December 22 4:00PM
Delayed by 15 minutes
8.63
0.13
(1.53%)
After Hours: 5:30PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
8.63
Bid
7.97
Ask
9.50
Volume
1,258,975
8.35 Day's Range 8.62
3.7599 52 Week Range 11.775
Market Cap
1.357B
Previous Close
8.45
Open
8.38
Last Trade
50
@
8.6
Last Trade Time
Financial Volume
$ 10,762,657
VWAP
8.5487
Average Volume (3m)
1,055,168
Shares Outstanding
157,217,427
Dividend Yield
-
PE Ratio
-16.55
Earnings Per Share (EPS)
-0.51
Revenue
58.44M
Net Profit
-80.74M

About Ocular Therapeutix Inc

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitation... Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.ocutx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Ocular Therapeutix Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OCUL. The last closing price for Ocular Therapeutix was $8.45. Over the last year, Ocular Therapeutix shares have traded in a share price range of $ 3.7599 to $ 11.775.

Ocular Therapeutix currently has 157,217,427 shares outstanding. The market capitalization of Ocular Therapeutix is $1.33 billion. Ocular Therapeutix has a price to earnings ratio (PE ratio) of -16.55.

Ask ADVFN Intelligence (AI)

OCUL Latest News

More News

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the...

December 13 2024
GlobeNewswire Inc.

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...

December 10 2024
GlobeNewswire Inc.

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second...

December 02 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

November 27 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

November 27 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

November 27 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

November 27 2024
Edgar (US Regulatory)

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world...

November 26 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

November 25 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

November 25 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.12-1.371428571438.759.218.156958498.70996984CS
40.040.465657741568.5910.258.158512009.29419335CS
12-0.26-2.92463442078.8911.7758.1510551689.89233908CS
262.7446.5195246185.8911.7755.8912934158.53274821CS
524.64116.2907268173.9911.7753.759917485327.42440509CS
1561.8527.28613569326.7811.7751.99511954785.99283146CS
2604.7119.5928753183.9324.31.99511193227.95788209CS

OCUL - Frequently Asked Questions (FAQ)

What is the current Ocular Therapeutix share price?
The current share price of Ocular Therapeutix is $ 8.63
How many Ocular Therapeutix shares are in issue?
Ocular Therapeutix has 157,217,427 shares in issue
What is the market cap of Ocular Therapeutix?
The market capitalisation of Ocular Therapeutix is USD 1.33B
What is the 1 year trading range for Ocular Therapeutix share price?
Ocular Therapeutix has traded in the range of $ 3.7599 to $ 11.775 during the past year
What is the PE ratio of Ocular Therapeutix?
The price to earnings ratio of Ocular Therapeutix is -16.55
What is the cash to sales ratio of Ocular Therapeutix?
The cash to sales ratio of Ocular Therapeutix is 22.87
What is the reporting currency for Ocular Therapeutix?
Ocular Therapeutix reports financial results in USD
What is the latest annual turnover for Ocular Therapeutix?
The latest annual turnover of Ocular Therapeutix is USD 58.44M
What is the latest annual profit for Ocular Therapeutix?
The latest annual profit of Ocular Therapeutix is USD -80.74M
What is the registered address of Ocular Therapeutix?
The registered address for Ocular Therapeutix is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Ocular Therapeutix website address?
The website address for Ocular Therapeutix is www.ocutx.com
Which industry sector does Ocular Therapeutix operate in?
Ocular Therapeutix operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
$ 80.55
(8.54%)
281.23M

OCUL Discussion

View Posts
Whalatane Whalatane 2 months ago
Scotiabank Initiates Coverage On Ocular Therapeutix with Sector Outperform Rating, Announces Price Target of $22

Kiwi
👍️0
Whalatane Whalatane 2 months ago
https://investors.ocutx.com/node/13236/pdf...trial enrolling ahead of schedule

Kiwi
👍️0
Whalatane Whalatane 2 months ago
As per the recent conference ...recruiting is going well and the speculation is that their trial will be fully enrolled ahead of schedule .
Eyelea ...the drug they will compete with ...is still increasing sales

Kiwi
👍️0
Whalatane Whalatane 5 months ago
Anybody out there ? Nice day to have a position in OCUL
Kiwi
👍️0
Whalatane Whalatane 9 months ago
OCUL. P2 data 4/5/24
REUTERS
10:03 AM ET 04/06/2024
April 6 (Reuters) - Ocular Therapeutix Inc (OCUL):
* OCULAR THERAPEUTIX™ ANNOUNCES POSITIVE PHASE 2 PAXTRAVA™ GLAUCOMA DATA AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024 ANNUAL MEETING
* OCULAR THERAPEUTIX INC (OCUL) - GENERALLY WELL TOLERATED WITH NO IMPACT ON CORNEAL HEALTH OBSERVED
* OCULAR THERAPEUTIX INC (OCUL) - CLINICALLY MEANINGFUL MEAN IOP REDUCTION OF ABOUT 24-30% FROM BASELINE OBSERVED OVER SIX MONTHS Source text for Eikon: Further company coverage:

Kiwi
👍️0
Monksdream Monksdream 9 months ago
OCUL under $10
👍️0
Monksdream Monksdream 9 months ago
OCUL 10Q due March 11
👍️0
glenn1919 glenn1919 1 year ago
OCUL....................................https://stockcharts.com/h-sc/ui?s=OCUL&p=W&b=5&g=0&id=p86431144783
👍️0
trendzone trendzone 2 years ago
Tard sells $6.00 call option at $0.15 at the close,apparently they were born yesterday.
👍️0
glenn1919 glenn1919 2 years ago
OCUL..........................................https://stockcharts.com/h-sc/ui?s=OCUL&p=W&b=5&g=0&id=p86431144783
👍️0
trendzone trendzone 2 years ago
Clueless fool sells $6.00 call option at $0.10 when they were just trading at $0.30,with the big rally going on in the stock today, what a total fool they are.
👍️0
cuggegrosse cuggegrosse 2 years ago
I chose OCUL to invest in because the market conditions should not effect the PPS(much),plus I can sell covered calls and make some monthly cash,besides they have products that are in demand !!!!
👍️ 1
cuggegrosse cuggegrosse 2 years ago
Yes I have noticed that
👍️ 1
Tzr250rg Tzr250rg 2 years ago
Ask is super thin wont take much to move. GLTUA
👍️0
cuggegrosse cuggegrosse 2 years ago
My eye doctor says Dextenza is a very good drug and he raccomends it !!!!!
👍️ 1
cuggegrosse cuggegrosse 2 years ago
DEXTENZA is doing very,very well,great revs expected in 2023
👍️ 1
cuggegrosse cuggegrosse 2 years ago
This company could go to $8.00 very eassy
👍️ 1
spotonge spotonge 2 years ago
boys need to wake up
👍️0
biotechslayr biotechslayr 2 years ago
Is anyone at all following OCUL into the end of the months binary? TKI data could be a game changer. Total TAM is ridiculous (look at REGN mcap!)
👍️ 1
oxnous oxnous 3 years ago
OCUL --charting


👍️0
oxnous oxnous 4 years ago
With the aging population, eye care is becoming an increasing concern. Dry eye, glaucoma, macular degeneration etc. will be expanding market sub sectors
👍️0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 04-29-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 4 years ago
Just In: $OCUL Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that its application for the creation of a Category I Current Procedural Ter...

In case you are interested OCUL - Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts
👍️0
whytestocks whytestocks 4 years ago
Breaking News: $OCUL Ocular Therapeutix(TM) Announces Topline Phase 1 Clinical Trial Results of OTX-CSI

OTX-CSI demonstrates improvement in signs and symptoms of Dry Eye Disease Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the ey...

Got this from OCUL - Ocular Therapeutix(TM) Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
👍️0
TheFinalCD TheFinalCD 4 years ago
OCUL 10.87 NEW HIGH OF DAY
👍️0
whytestocks whytestocks 4 years ago
Just In: $OCUL Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary, unaudited net product revenue for the third quarter ended Septe...

Find out more OCUL - Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter
👍️0
now invest now invest 5 years ago
Thus far OCUL is trading nicely!!
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 05-22-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 03-04-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
edwardport edwardport 5 years ago
near term 10% projected increase in market price

closed on 2/7/20 @ $5.21
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 02-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 01-03-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 11-29-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
TFMG TFMG 5 years ago
OCUL - POSSIBLE 25% TREND MOVE ON THE DAILY

Ocular Therapeutix , Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

SHORT INTEREST
8.24M 07/15/19

P/E Current
-2.78

P/E Ratio (with extraordinary items)
-2.92

Average Recommendation: OVERWEIGHT

Average Target Price: 9.67

👍️0
tste9 tste9 5 years ago
Great news! BUT, hoped for more volume price etc. wow
GLA
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 07-26-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a ...

Got this from Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
👍️0
smallbio smallbio 5 years ago

Is DEXTENZA currently only targeting medicare patients, as there is no private insurance company will reimburse the cost?
👍️0
tste9 tste9 5 years ago
What is up with this little piggy, lately! #&*#@*
👍️0
tste9 tste9 5 years ago
Great news thanks for post. Do you know of any web site that posts OCUL sales per week. Thank you. GL
👍️0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States

Pass-through payment status and C-code from the Centers for Medicare and Medicaid Services (CMS) now active Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and ...

In case you are interested https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-commercial-launch-of-dextenza-x-8439742.html
👍️0
swingingRichard swingingRichard 5 years ago
Shorted 10,000 shares. Looking good.
👍️0
tste9 tste9 6 years ago
Shorts ease out as usual. criminal how shorts manipulate SP then just slither out unharmed. GLA
👍️0
tste9 tste9 6 years ago
YEA BABY!
👍️0
ClayTrader ClayTrader 6 years ago
* * $OCUL Video Chart 06-21-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 6 years ago
News: $OCUL Ocular Therapeutix(TM) Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

DEXTENZA ® Now Approved for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

Find out more https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-fda-approval-of-supplemental-new-drug-application-snda-for-dextenza-xae-0-4-dexamethasone-intracanalicular-insert-for-ophthalmic-use-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery-8394606.html
👍️0
ClayTrader ClayTrader 6 years ago
* * $OCUL Video Chart 06-11-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Tzr250rg Tzr250rg 6 years ago
low volume today
👍️0
whytestocks whytestocks 6 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved t...

Got this from https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza-xae--8261962.html
👍️0
ClayTrader ClayTrader 6 years ago
* * $OCUL Video Chart 05-21-2019 * *

Link to Video - click here to watch the technical chart video

👍️0

Your Recent History

NASDAQ
OCUL
Ocular Therapeutix
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads